<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00023790</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU1Y97</org_study_id>
    <secondary_id>U01CA062502</secondary_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CWRU-1Y97</secondary_id>
    <secondary_id>NCI-T99-0007</secondary_id>
    <secondary_id>CASE-1Y97</secondary_id>
    <nct_id>NCT00023790</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin</brief_title>
  <official_title>Phase I Trial of PC 4-PDT (NSC 676418) for Cutaneous Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to&#xD;
      light to kill tumor cells. This may be effective treatment for skin cancer and cancer that is&#xD;
      metastatic to the skin.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of photodynamic therapy in treating&#xD;
      patients who have either squamous cell or basal cell carcinoma of the skin or solid tumors&#xD;
      metastatic to the skin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of silicon phthalocyanine 4 (Pc 4) when&#xD;
           administered with a fixed dose of light in patients with advanced cutaneous&#xD;
           malignancies.&#xD;
&#xD;
        -  Determine the MTD of the light when administered with a fixed dose of study drug in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of Pc 4 in these patients.&#xD;
&#xD;
        -  Determine the clinical antitumor response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive silicon phthalocyanine 4 (Pc 4) IV over 2 hours on day 1 followed by light&#xD;
      therapy over 30-60 minutes on day 2. Treatment repeats in 6 weeks for a total of 2 courses in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of Pc 4 and a fixed dose of light until the&#xD;
      maximum tolerated dose (MTD) of Pc 4 is determined. The MTD is defined as the dose preceding&#xD;
      that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD for Pc 4 is&#xD;
      determined, additional patients are treated with a fixed dose of Pc 4 (2 dose levels below&#xD;
      the MTD) and escalating doses of light until the MTD is determined. The MTD of light is&#xD;
      defined as above.&#xD;
&#xD;
      Patients are followed at 6 weeks (or 8 weeks if treated lesion on lower extremity has not&#xD;
      healed) and then every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 25-30 patients will be accrued for this study annually.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual&#xD;
  </why_stopped>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity as assessed by physical exam and laboratory data.</measure>
    <time_frame>weekly for 4 weeks and in week 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease response as measured by skin assessment and photography</measure>
    <time_frame>weekly for 4 weeks and in week 6</time_frame>
  </primary_outcome>
  <enrollment type="Actual">3</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Lymphoma</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Non-melanomatous Skin Cancer</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>silicon phthalocyanine 4</intervention_name>
    <description>Patients receive silicon phthalocyanine 4 (Pc 4) IV over 2 hours on day 1 followed by light therapy over 30-60 minutes on day 2. Treatment repeats in 6 weeks for a total of 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of Pc 4.</description>
    <other_name>Pc-4 (Silicone phthalocyanine)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed tumor for which no potential curative therapy exists (e.g.,&#xD;
             surgery, radiotherapy, or systemic chemotherapy)&#xD;
&#xD;
               -  The following tumor types are eligible:&#xD;
&#xD;
                    -  Cutaneous nodular metastatic breast carcinoma lesion with loco-regional&#xD;
                       cutaneous, soft tissue, or chest wall involvement&#xD;
&#xD;
                         -  No chest wall recurrence without prior radiotherapy&#xD;
&#xD;
                         -  Other metastatic sites allowed provided patient is concurrently&#xD;
                            receiving hormonal therapy or trastuzumab (Herceptin) of at least 4&#xD;
                            weeks duration&#xD;
&#xD;
                    -  Cutaneous or superficial subcutaneous nodular metastatic head and neck&#xD;
                       lesion&#xD;
&#xD;
                    -  Cutaneous nodular Kaposi's sarcoma lesion&#xD;
&#xD;
                    -  Stage IA-IIB or IVA cutaneous T-cell lymphoma (CTCL)&#xD;
&#xD;
                         -  CTCL patches, plaques, or tumors with a surface area of up to 25 cm^2&#xD;
                            if other areas of involved skin are blocked from therapy&#xD;
&#xD;
                    -  Squamous cell or basal cell carcinoma of the skin that is not eligible for&#xD;
                       standard therapy (e.g., cryosurgery, radiotherapy, electrodesiccation and&#xD;
                       curettage, or excision)&#xD;
&#xD;
                    -  Cutaneous and subcutaneous metastasis from any solid tumor (e.g., thoracic,&#xD;
                       gastrointestinal, or genitourinary cancers or sarcomas)&#xD;
&#xD;
          -  Bidimensionally measurable disease&#xD;
&#xD;
               -  No more than 2 lesions may be treated&#xD;
&#xD;
          -  No single area greater than 36 cm^2 may be treated (maximum of 25 cm^2 tumor mass with&#xD;
             a 1 cm margin)&#xD;
&#xD;
          -  Tumor treatable by surface (non-contact) light illumination&#xD;
&#xD;
          -  Skin type I-III&#xD;
&#xD;
          -  No tumors of the eyelids&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST/ALT no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2 times ULN&#xD;
&#xD;
          -  No history of hepatic cirrhosis&#xD;
&#xD;
          -  No hepatic disease requiring therapy&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
          -  No renal disease requiring therapy&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No significant congestive heart failure requiring therapy&#xD;
&#xD;
          -  No peripheral vascular disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Antinuclear antibody negative&#xD;
&#xD;
          -  No sepsis&#xD;
&#xD;
          -  No prior allergic or hypersensitivity reaction to paclitaxel vehicle&#xD;
&#xD;
          -  No known photosensitivity diseases such as porphyria, systemic lupus erythematosus,&#xD;
             xeroderma pigmentosum, or polymorphous light eruption&#xD;
&#xD;
          -  No symptomatic collagen vascular disease&#xD;
&#xD;
          -  Insulin-dependent or adult-onset diabetes mellitus allowed provided there are no lower&#xD;
             extremity lesions&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior systemic chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior ultraviolet B light therapy or psoralen-ultraviolet&#xD;
             light therapy to non-study lesions/areas&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 5 days since prior warfarin&#xD;
&#xD;
          -  At least 4 weeks since prior investigational drugs&#xD;
&#xD;
          -  At least 4 weeks since prior local therapy to study lesions&#xD;
&#xD;
          -  At least 6 months since prior photodynamic therapy&#xD;
&#xD;
          -  No concurrent aspirin, aspirin-containing medications, or non-steroidal&#xD;
             anti-inflammatory drugs (e.g., ibuprofen, indomethacin, or cyclo-oxygenase [COX]-1 and&#xD;
             COX-2 inhibitors)&#xD;
&#xD;
          -  No other concurrent photosensitizing medications such as tetracyclines, psoralens,&#xD;
             nalidixic acid, griseofulvin, sulfa drugs, hydrochlorothiazide, furosemide,&#xD;
             phenothiazines, or amiodarone&#xD;
&#xD;
          -  No concurrent therapeutic dosages of warfarin (non-therapeutic dosages allowed)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scot C. Remick, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/ct2/results?term=cwru1y97</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 23, 2011</last_update_submitted>
  <last_update_submitted_qc>August 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>basal cell carcinoma of the skin</keyword>
  <keyword>squamous cell carcinoma of the skin</keyword>
  <keyword>recurrent skin cancer</keyword>
  <keyword>classic Kaposi sarcoma</keyword>
  <keyword>immunosuppressive treatment related Kaposi sarcoma</keyword>
  <keyword>AIDS-related Kaposi sarcoma</keyword>
  <keyword>recurrent Kaposi sarcoma</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV basal cell carcinoma of the lip</keyword>
  <keyword>stage IV verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage IV mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage IV adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent basal cell carcinoma of the lip</keyword>
  <keyword>recurrent verrucous carcinoma of the oral cavity</keyword>
  <keyword>recurrent mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>recurrent adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent verrucous carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>skin metastases</keyword>
  <keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silicon</mesh_term>
    <mesh_term>Silicon phthalocyanine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

